Floor Talk with Judy Shaw
OS Therapies CEO on clinical advancements in immunotherapy for osteosarcoma
4m 43s
Paul Romness, CEO of OS Therapies, tells us about the company’s progress since its August 2024 IPO and its latest clinical advancements in immunotherapy for osteosarcoma and other solid tumors on #NYSEFloorTalk with Judy Shaw.
Up Next in 2025
-
CoachHub CEO on making coaching more ...
Matti Niebelschütz, CEO & Co-Founder of CoachHub, discusses the future of coaching in the ‘people era,’ how AI is making coaching more accessible, and the role of AIMY™ AI Coach in transforming workplace learning on #NYSEFloorTalk with Judy Shaw.
-
RADZ Group has acquired RSE, marking ...
The RADZ Group has acquired RSE, marking an exciting step forward for both companies. Chris Holben, President of RSE, and Rachel Zillner, Co-Founder of The RADZ Group, join Judy Shaw #NYSEFloorTalk to discuss what this means for the future.
-
OS Therapies CEO on its latest clinic...
Paul Romness, CEO of OS Therapies, tells us about the company’s progress since its August 2024 IPO and its latest clinical advancements in immunotherapy for osteosarcoma and other solid tumors on #NYSEFloorTalk with Judy Shaw.
